Kotani D, Kuboki Y, Horasawa S, et al. - The safety and efficacy of trifluridine/tipiracil plus bevacizumab vs trifluridine/tipiracil monotherapy in patients with heavily pretreated metastatic colorectal cancer (mCRC) were investigated in clinical settings. Reviewing records of patients with mCRC refractory to standard therapies, they identified 60 patients who initiated trifluridine/tipiracil plus bevacizumab and 66 patients who initiated trifluridine/tipiracil monotherapy. Outcomes revealed the achievement of prolonged progression-free survival (PFS) and higher 16-week PFS rate in correlation to administering trifluridine/tipiracil plus bevacizumab vs trifluridine/tipiracil monotherapy in patients with heavily pretreated mCRC with manageable toxicities.